Physician Liver Function Test (LFT) Monitoring for Tykerb Pts
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01462552|
Recruitment Status : Completed
First Posted : October 31, 2011
Last Update Posted : April 15, 2015
In July 2008, the lapatinib (Tykerb) Prescribing Information (label) was updated to include a boxed warning related to hepatotoxcity and detailed instructions for monitoring liver function before and during lapatanib exposure. For patient safety, it is of interest to know the extent to which providers are adherent with these guidelines for hepatic monitoring of lapatanib users.
Thus, the aim of this study is to determine if physicians conduct liver function testing prior to prescribing lapatanib and at regular intervals during exposure, and if they withdraw lapatanib, and do not re-treat, for patients who demonstrate severe liver enzyme elevations while exposed. These aims will be tested in the "Pre-label" (prior to the boxed warning) and "Post-label" (after the boxed warning) periods to determine if physician adherence to the guidelines changed as a result of the warning.
Specifically, the boxed warning provided the following guidance:
"Hepatotoxicity (alanine transaminase or aspartate transaminase >3 times the upper limit of normal and total bilirubin >1.5 times the upper limit of normal) has been observed in clinical trials (<1% of patients) and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after initiation of treatment. Liver function tests (transaminases, bilirubin, and alkaline phosphatase) should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. If changes in liver function are severe, therapy with lapatanib should be discontinued and patients should not be re-treated with lapatanib"
The following objectives will be assessed and compared among patients prescribed lapatanib before and after the addition of detailed guidance on liver function testing to the product label on July 9, 2008:
- Objective 1: Determine if physicians perform liver funtion tests (LFTs) prior to prescribing lapatanib (baseline)
- Objective 2: Describe the prevalence of LFT elevations at baseline
- Objective 3: Determine if physicians routinely perform LFTs during the duration of lapatanib exposure
- Objective 4: Describe the cumulative incidence and incidence rate of LFT elevations during lapatanib exposure
- Objective 5: Describe patients that experience severe LFT elevations during lapatanib exposure and calculate the proportion that have lapatanib discontinued and are not re-treated
To achieve these objectives, an observational retrospective cohort study will be conducted using the United States Oncology Electronic Medical Records database. The study population will consist of females with a diagnosis of metastatic breast cancer and a documented order for Lapatanib from January 1, 2007 - December 31, 2009. Patients will be categorized by whether they initiated Lapatanib before or after the July 9, 2008 label change.
'Pre Label': Initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
'Post Label': Initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
The exposure in this study is lapatanib oral medication. The date of initiation of lapatanib will be the index date. Lapatanib exposure period(s) will be defined from the index date through to the end of the study period (June 30, 2008 for pre-label group or June 30, 2010 for post-label group).
The project will use proportions and two estimates of incidence (cumulative incidence and incidence rates using person-time) to describe the outcomes of interest among the users of Lapatanib before and after the label change. The following LFTs will be considered:
- alanine transaminase (ALT)
- aspartate transaminase (AST)
- alkaline phosphatise (ALP)
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Official Title:||Assessment of Physician Compliance to Recommended Liver Function Test Monitoring for Tykerb Patients|
|Study Start Date :||December 2010|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||August 2011|
Metastatic breast cancer pre-label group
Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
Prescription of lapatinib (Tykerb)
Metastatic breast cancer post-label group
Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
Prescription of lapatinib (Tykerb)
- The change in proportion of patients that receive liver function tests prior to the initiation of lapatanib [ Time Frame: Within 30 days, 60 days, or 90 days prior to (and including) the day that lapatanib was initiated ]
- The change in prevalence of LFT elevations prior to the initiation of lapatanib [ Time Frame: Within 30 days, 60 days or 90 days prior to (and including) the day that lapatanib was initiated ]
- The proportion of patients that have LFT performed routinely (at least every 6 weeks) while exposed to lapatanib [ Time Frame: During entire lapatanib exposure (Based on index date between January 2007 - June 2010). ]
- The incidence of LFT elevations while exposed to lapatanib [ Time Frame: During entire lapatanib exposure (Based on index date between January 2007 - June 2010). ]
- The proportion of patients with a severe LFT elevation that have lapatanib withdrawn, and are not re-treated [ Time Frame: During entire lapatanib exposure (Based on index date between January 2007 - June 2010). ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01462552
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|